![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
Stock, Sophia 
ORCID: https://orcid.org/0000-0002-5072-5013; Benmebarek, Mohamed-Reda ORCID: https://orcid.org/0000-0002-1201-7067; Kluever, Anna-Kristina ORCID: https://orcid.org/0000-0001-6246-6082; Darowski, Diana ORCID: https://orcid.org/0000-0002-8778-7920; Jost, Christian ORCID: https://orcid.org/0000-0002-4169-5879; Stubenrauch, Kay-Gunnar; Benz, Joerg; Freimoser-Grundschober, Anne ORCID: https://orcid.org/0000-0001-5715-3639; Moessner, Ekkehard; Umana, Pablo; Subklewe, Marion ORCID: https://orcid.org/0000-0001-9154-9469; Endres, Stefan ORCID: https://orcid.org/0000-0002-4703-537X; Klein, Christian ORCID: https://orcid.org/0000-0001-7594-7280 und Kobold, Sebastian ORCID: https://orcid.org/0000-0002-5612-4673
(2022):
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
In: Journal for ImmunoTherapy of Cancer, Bd. 10, Nr. 7, e005054
[PDF, 17MB]
ORCID: https://orcid.org/0000-0002-5072-5013; Benmebarek, Mohamed-Reda ORCID: https://orcid.org/0000-0002-1201-7067; Kluever, Anna-Kristina ORCID: https://orcid.org/0000-0001-6246-6082; Darowski, Diana ORCID: https://orcid.org/0000-0002-8778-7920; Jost, Christian ORCID: https://orcid.org/0000-0002-4169-5879; Stubenrauch, Kay-Gunnar; Benz, Joerg; Freimoser-Grundschober, Anne ORCID: https://orcid.org/0000-0001-5715-3639; Moessner, Ekkehard; Umana, Pablo; Subklewe, Marion ORCID: https://orcid.org/0000-0001-9154-9469; Endres, Stefan ORCID: https://orcid.org/0000-0002-4703-537X; Klein, Christian ORCID: https://orcid.org/0000-0001-7594-7280 und Kobold, Sebastian ORCID: https://orcid.org/0000-0002-5612-4673
(2022):
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
In: Journal for ImmunoTherapy of Cancer, Bd. 10, Nr. 7, e005054
[PDF, 17MB]